PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$88.06

01 Dec
2023

-0.350

OPEN

$87.54

-0.40%

HIGH

$88.63

125,671

LOW

$87.28

TARGET
$63.875 -27.5% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx 58.1 76.2 xxx
DPS (cps) xxx 30.0 38.6 xxx
EPS Growth xxx 36.4% 31.1% xxx
DPS Growth xxx 36.4% 28.7% xxx
PE Ratio xxx N/A 115.6 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 51.6% 50.7% xxx

Dividend yield today if purchased 3 years ago: 1.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.34

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 17c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx58.1
DPS All xxxxxxxxxxxxxxx30.0
Sales/Revenue xxxxxxxxxxxxxxx124.9 M
Book Value Per Share xxxxxxxxxxxxxxx132.9
Net Operating Cash Flow xxxxxxxxxxxxxxx64.8 M
Net Profit Margin xxxxxxxxxxxxxxx48.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx50.43 %
Return on Invested Capital xxxxxxxxxxxxxxx49.84 %
Return on Assets xxxxxxxxxxxxxxx33.77 %
Return on Equity xxxxxxxxxxxxxxx50.43 %
Return on Total Capital xxxxxxxxxxxxxxx68.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx38.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx121 M
Price To Book Value xxxxxxxxxxxxxxx49.40

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.4 M
Capex % of Sales xxxxxxxxxxxxxxx5.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx33 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

27/09/2023

3

Hold

$74.00

-15.97%

Pro Medicus has signed its largest deal to date in the US in a 10-year contract with Baylor Scott & White Health, one of the largest not-for-profit healthcare systems in Texas. Contract revenue is $140m over the duration and includes a full suite of services, fully cloud-based.

Morgans classifies the contract as a one-off and asserts this does not roll through to long-term assumptions for new contracts growth, although it does signal the potential "monster" contracts that lay within the US health system.

The broker's main concern is valuation and will, therefore, wait for some share price weakness to add to positions. Hold maintained. Target is $74, raised from $66, as upgraded assumptions are rolled through.

FORECAST
Morgans forecasts a full year FY24 dividend of 37.00 cents and EPS of 74.00 cents.
Morgans forecasts a full year FY25 dividend of 53.00 cents and EPS of 107.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

PME STOCK CHART